Skip to content

Tamsulosin

alpha-Adrenergic Blocker — GENITO URINARY SYSTEM AND SEX HORMONES

Also known as: LY-253352, tamsulosin HCl, tamsulosin hydrochloride

OfpFDA approvedATC G04CA02ATC G04CA52ATC G04CA53

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Tamsulosin is an ofp drug in the alpha-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Adrenergic alpha-Antagonists. DrugCentral lists 15 molecular targets, including ADRA1A, Adra1a and ADRA1D. Recorded indications include Benign prostatic hyperplasia.

  • Approval status: ofp (first approved 1997 by the FDA).
  • Drug class: alpha-Adrenergic Blocker.
  • Mechanism of action: Adrenergic alpha-Antagonists.
  • Molecular targets: ADRA1A, Adra1a, ADRA1D and Adra1d (15 listed in DrugCentral).
  • Indications: Benign prostatic hyperplasia.
  • ATC code: G04CA02 (Alpha-adrenoreceptor antagonists).
  • Molecular formula: C20H28N2O5S; molecular weight 408.51 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Benign prostatic hyperplasia

Contraindications (11)

  • Breastfeeding (mother)
  • Cataract surgery
  • Disease of liver
  • Dizziness
  • High-Grade Prostate Cancer
  • Intraoperative floppy iris syndrome
  • Oligozoospermia
  • Orthostatic hypotension
  • Pregnancy, function
  • Priapism
  • Syncope

Mechanism & targets

Mechanism of action (MoA)Adrenergic alpha-Antagonists
Established pharmacologic classalpha-Adrenergic Blocker

Molecular targets (15)

TargetGeneActionActivity
Alpha-1A adrenergic receptorADRA1AunknownKi 10.54
Alpha-1A adrenergic receptorAdra1aunknownKi 10.52
Alpha-1D adrenergic receptorADRA1DunknownKi 10.24
Alpha-1D adrenergic receptorAdra1dunknownKi 10.15
Alpha-1A adrenergic receptorADRA1AunknownKi 9.90
Alpha-1B adrenergic receptorADRA1BunknownKi 9.70
D(3) dopamine receptorDRD3unknownKi 9.55
Alpha-1B adrenergic receptorADRA1BunknownKi 9.21
5-hydroxytryptamine receptor 1AHTR1AunknownKi 9.10
Alpha-2B adrenergic receptorAdra2bunknownKi 8.17
Alpha-2C adrenergic receptorADRA2CunknownKi 8.10
D(2) dopamine receptorDRD2unknownKi 7.89
Alpha-2A adrenergic receptorADRA2AunknownKi 7.87
5-hydroxytryptamine receptor 7HTR7unknownKi 7.08
Serotonin 1 (5-HT1) receptorHtr1a|Htr1b|Htr1d|Htr1funknownKi 6.03

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1997-04-15FDA—BOEHRINGER INGELHEIM

ATC classification

ATC codeTherapeutic hierarchy
G04CA02GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists
G04CA52GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists
G04CA53GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists
G04CA54GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • FDA label: CYP2D6 · Actionable PGx
  • HCSC label: CYP2D6 · Informative PGx
  • Swissmedic label: CYP2D6, CYP3A4 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Urinary retention726.5
Fall671.5
Syncope640.9
Maternal exposure during pregnancy635.0
Haematuria584.1
Alopecia577.3
Synovitis568.9
Benign prostatic hyperplasia559.8
Pemphigus535.8
Glossodynia484.1
Dizziness460.3
Orthostatic hypotension441.3

Chemical structure

Molecular formulaC20H28N2O5S
Molecular weight408.51 g/mol
CAS number106133-20-4
InChIKeyDRHKJLXJIQTDTD-OAHLLOKOSA-N
PubChem CID129211
CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tamsulosin used for?

DrugCentral lists the following indications for Tamsulosin: Benign prostatic hyperplasia.

How does Tamsulosin work?

Tamsulosin is classified as Adrenergic alpha-Antagonists; its molecular targets in DrugCentral include ADRA1A, Adra1a, ADRA1D and Adra1d.

When was Tamsulosin first approved?

Tamsulosin was first approved by the FDA in 1997.

What drug class does Tamsulosin belong to?

Tamsulosin is in the alpha-Adrenergic Blocker class.

What is the chemical formula of Tamsulosin?

Tamsulosin has the molecular formula C20H28N2O5S and a molecular weight of 408.51 g/mol.

Browse: all drugs starting with T · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1997-04-15
AgencyFDA
Targets15
Indications1
FormulaC20H28N2O5S
DrugCentral ID2562
Interactive profile